SCA
TGTX icon

Sassicaia Capital Advisers’s TG Therapeutics TGTX Stock Holding History

Sassicaia Capital Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-23,000
Closed -$272K – 49
2022
Q4 		$272K Buy
+23,000
New +$167K 0.68% 21

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Sassicaia Capital Advisers's TGTX Position: Q1 2023 in Review

Sassicaia Capital Advisers sold out of TG Therapeutics (TGTX) in Q1 2023, closing a stake of 23,000 shares — an estimated $272K sold.

Sassicaia Capital Advisers first reported a position in TGTX in Q4 2022 and held it in 1 quarter. The position peaked at $272K in Q4 2022. 214 funds tracked by Wall St. Rank hold TGTX as of Q1 2023.

  • Sassicaia Capital Advisers reported no remaining TG Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Sassicaia Capital Advisers sold 23,000 TG Therapeutics shares in Q1 2023, an estimated $272K.
  • Sassicaia Capital Advisers first reported a position in TG Therapeutics in Q4 2022 and held it in 1 quarter.
  • Sassicaia Capital Advisers's TG Therapeutics position peaked at $272K in Q4 2022.
  • 214 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2023.

Based on Sassicaia Capital Advisers's 13F filing for Q1 2023, filed 15 May 2023.